Name (Synonyms) | Correlation | |
---|---|---|
drug1425 | Macrolide administered for up to 14 days Wiki | 0.71 |
drug1227 | Interferon-β1a Wiki | 0.71 |
drug1424 | Macrolide administered for 3-5 days Wiki | 0.71 |
drug949 | Fixed-duration Hydrocortisone Wiki | 0.71 |
drug1932 | Protocolised mechanical ventilation strategy Wiki | 0.71 |
drug2254 | Shock-dependent hydrocortisone Wiki | 0.71 |
drug1092 | Hydroxychloroquine + lopinavir/ritonavir Wiki | 0.71 |
drug1820 | Piperacillin-tazobactam Wiki | 0.71 |
drug156 | Amoxicillin-clavulanate Wiki | 0.71 |
drug950 | Fixed-duration higher dose Hydrocortisone Wiki | 0.71 |
drug532 | Ceftriaxone Wiki | 0.71 |
drug591 | Clungene rapid test cassette Wiki | 0.71 |
drug946 | Five-days oseltamivir Wiki | 0.71 |
drug1523 | Moxifloxacin or Levofloxacin Wiki | 0.71 |
drug531 | Ceftaroline Wiki | 0.71 |
drug2472 | Ten-days oseltamivir Wiki | 0.71 |
drug2263 | Simvastatin Wiki | 0.50 |
drug2197 | Sarilumab Wiki | 0.32 |
drug159 | Anakinra Wiki | 0.27 |
drug1372 | Lopinavir/ritonavir Wiki | 0.22 |
drug2662 | Vitamin C Wiki | 0.21 |
drug658 | Convalescent plasma Wiki | 0.18 |
drug2527 | Tocilizumab Wiki | 0.13 |
drug1086 | Hydroxychloroquine Wiki | 0.07 |
Name (Synonyms) | Correlation | |
---|---|---|
D054556 | Venous Thromboembolism NIH | 0.27 |
D020141 | Hemostatic Disorders NIH | 0.21 |
D001778 | Blood Coagulation Disorders NIH | 0.21 |
D013923 | Thromboembolism NIH | 0.19 |
D011014 | Pneumonia NIH | 0.04 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001928 | Abnormality of coagulation HPO | 0.21 |
HP:0001907 | Thromboembolism HPO | 0.17 |
HP:0002090 | Pneumonia HPO | 0.04 |
There are 2 clinical trials
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.
Description: Primary end-point for patients with suspected or proven COVID-19 pandemic infection
Measure: Days alive and not receiving organ support in ICU Time: Day 21Description: EQ5D-5L and WHODAS 2.0 (not completed in all regions)
Measure: Health-related Quality of life assessment Time: 6 monthsDescription: Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital
Measure: Destination at time of hospital discharge Time: Free text Day 90Description: Antibiotic Domain specific outcome
Measure: Occurrence of multi-resistant organism colonisation/infection Time: Day 90, censored at hospital dischargeDescription: Antibiotic Domain specific outcome
Measure: Occurrence clostridium difficile Time: Day 90, censored at hospital dischargeDescription: Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.
Measure: Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death Time: Day 90, censored at hospital dischargeDescription: Antiviral Domain specific outcome. Only required at selected sites.
Measure: Change from baseline influenza virus levels in upper and lower respiratory tract specimens Time: Day 3, up to Day 7Description: COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpoint
Measure: Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing) Time: Day 90, censored at hospital dischargePublished papers evaluating coagulopathy on COVID-19 patients indicate a higher incidence of thromboembolic events, sometimes, as high as 20%. Such events increase ICU admissions and are associated with death. Considering the importance of thromboembolic events concurring to deteriorate clinical state, we propose to conduct a parallel pragmatic open-label randomized controlled trial to determine the effect of therapeutic anticoagulation compared to standard care in hospitalized patients with COVID-19 and with low oxygen saturation.
Description: Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.
Measure: Composite main outcome Time: up to 28 daysDescription: All-cause death
Measure: All-cause death Time: 28 daysDescription: Composite outcome of ICU admission or all-cause death
Measure: Composite outcome of ICU admission or all-cause death Time: 28 daysDescription: Major bleeding
Measure: Major bleeding Time: 28 daysDescription: Red Blood Cell transfusion (greater than or equal to 1 unit)
Measure: Number of participants who received red blood cell transfusion Time: 28 daysDescription: Transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate
Measure: Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate. Time: 28 daysDescription: Hospital-free days alive up to day 28
Measure: Number of hospital-free days alive up to day 28 Time: 28 daysDescription: ICU-free days alive up to day 28
Measure: Number of ICU-free days alive up to day 28 Time: 28 daysDescription: Ventilator-free days alive up to day 28
Measure: Number of ventilator-free days alive up to day 28 Time: 28 daysDescription: Venous thromboembolism
Measure: Number of participants with venous thromboembolism Time: 28 daysDescription: Arterial thromboembolism
Measure: Number of participants with arterial thromboembolism Time: 28 daysDescription: Heparin induced thrombocytopenia
Measure: Number of participants with heparin induced thrombocytopenia Time: 28 days